We at Bayer strive to overcome the biggest obstacles holding back modern drug discovery to develop new medicines for many difficult-to-treat diseases. Explore how we are reinventing drug discovery and pushing the limits of druggability.
RNA-Targeting Small Molecules
Many proteins involved in harmful disease processes cannot be targeted by drugs – they are “undruggable”. Targeting them at the level of RNA with RNA-targeting small molecule drugs could be the entry point yet into an unexplored universe of new treatment options for patients.
By utilizing the natural cellular disposal mechanism to degrade unwanted or harmful proteins, PROTACs® may offer a different approach to treating disease.
By rethinking drug discovery, chemoproteomics opens up new treatment options for some of the most serious diseases affecting millions all over the world.